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SUMMARY 
 
Aging is a significant risk factor for cancer in several tissues, including the prostate. 
Defining the kinetics of age-related changes in these tissues is critical for identifying 
regulators of aging and evaluating interventions to slow the aging process and reduce 
disease risk. An altered microenvironment is characteristic of prostatic aging in mice. 
Whether features of aging in the prostate emerge predominantly in old age or earlier in 
.CC-BY-NC-ND 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted June 20, 2020. . https://doi.org/10.1101/2020.06.18.160556doi: bioRxiv preprint 
adulthood has not previously been established. Using comprehensive immune profiling 
and time-course analysis, we show that populations of T and B lymphocytes increase in 
the mouse prostate between 6 and 12 months of age. When comparing the prostate to 
other urogenital tissues, we found similar features of age-related inflammation in the 
mouse bladder. In summary, our study offers new insight into the kinetics of prostatic 
inflammaging and the window when interventions to slow down age-related changes 
may be most effective. 
 
INTRODUCTION 
 
Aging is associated with the dysfunction of many different cellular and molecular 
processes which results in the development of age-related pathologies including cancer 
(Lopez-Otin et al., 2013). The risk of prostate cancer increases with age (Leitzmann and 
Rohrmann, 2012), but the mechanisms driving increased disease risk with age are 
poorly understood. One well-established aspect of aging is the development of chronic 
low-grade inflammation, termed “inflammaging” (Franceschi et al., 2018). Chronic 
inflammation in the benign prostate increases the risk for developing high-grade 
prostate cancer later in life (Gurel et al., 2014). Prostatic inflammation is associated with 
luminal progenitor cells that can serve as target cells for human prostate cancer 
initiation (Liu et al., 2016). In both mice and humans, the population of luminal 
progenitor cells in the prostate increases with age (Crowell et al., 2019), expanding the 
pool of potential target cells for transformation. 
 
While mice do not naturally develop prostate cancer, alterations in the hormonal milieu 
and genetic alterations in the epithelium can cooperate with aging to promote 
tumorigenesis (Grabowska et al., 2014). Importantly, the cellular changes that define 
aging phenotypes in the human prostate are conserved in the aging mouse prostate, 
indicating that the mouse is an ideal model system to investigate factors that regulate 
age-related changes to the prostate (Crowell et al., 2019). The aging mouse prostate is 
characterized by increased inflammation and stromal disorganization (Bianchi-Frias et 
al., 2010). Compared with sexually mature 3-month-old mice, prostates of 24-month-old 
mice are enriched for T and B lymphocytes. Whether prostatic inflammation emerges 
primarily in old age or steadily increases throughout adulthood has not been 
established. 
 
Efforts to slow age-related changes have garnered considerable interest over the past 
decade. Caloric restriction, as well as mTOR inhibition, show promise in delaying aging 
phenotypes and extending lifespan in model organisms (Heilbronn and Ravussin, 2003; 
Johnson et al., 2013). Pharmacological enhancement of NAD+ levels has also been 
shown to reverse aging phenotypes (Rajman et al., 2018). Anti-inflammatory strategies 
represent another option for combating the effects of aging (Pedersen, 2009). 
Understanding the dynamics of age-related changes is essential for defining the window 
in which interventions are most efficacious. 
 
We sought to define the kinetics of mouse prostatic inflammation throughout adulthood 
at single-cell resolution using mass cytometry, or cytometry by time-of-flight (CyTOF), 
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which has been previously reported by our group and others to study immune cells in 
the prostate (Crowell et al., 2019; Fox et al., 2019; Wang et al., 2016). We also set out 
to determine how aging-associated inflammation in the prostate compares with other 
urogenital tissues susceptible to age-related cancers. Our study revealed features of old 
age in the prostate far earlier than previously reported, with evidence of increased 
lymphocyte infiltration emerging between 6 and 12 months of age. Age-related changes 
in immune profiles were shared by the mouse prostate and bladder, suggesting 
common features of inflammaging in distinct genitourinary tissues. 
 
RESULTS 
 
Identification of distinct immune subsets in mouse prostate using mass 
cytometry 
 
Upon evaluating prostates from mice at various ages between 1 and 16 months, we 
observed a positive correlation between age and wet prostate weight (ρ = 0.6673, P
ρ
 < 
0.001) characterized by a rapid increase in weight in pre-pubescent mice (< 3 months 
old) (Figure S1A). This growth model is consistent with the rapid, androgen-dependent 
growth of the prostate which occurs postnatally until sexual maturity at 2–3 months of 
age (Dutta and Sengupta, 2016; Sugimura et al., 1986). Our data also demonstrates 
that the mouse prostate continues to grow after reaching adulthood. Analyzing post-
pubertal adult mice from 3 to 16 months of age, we observed a positive correlation 
between age and prostate weight (ρ = 0.5144, P
ρ
 < 0.01), with a significant increase in 
mass at 16 months of age (p < 0.05) (Figure S1A). Age was also positively correlated 
with the percentage of CD45+ immune cells in the prostate, as measured by flow 
cytometry (ρ = 0.7034, P
ρ
 < 0.01) (Figure S1B), consistent with age-related prostatic 
inflammation.   
 
We used CyTOF to characterize age-related changes in the immune microenvironment 
of the prostate throughout adulthood. Prostates were isolated from adult mice aged 3, 6, 
9, 12, and 16 months (each n = 4), and dissociated cells were stained with a panel of 19 
metal-tagged antibodies designed to label a broad variety of immune cell types (Table 1 
and Figure 1A). Single live immune cells were concatenated and clustered as a whole 
to allow for comparisons of phenotypically-identical clusters using the t-distributed 
stochastic neighbor embedding (t-SNE) algorithm for dimensional reduction and 
visualization (Figures 1A and 1B and Figure S2A). Based on expression of immune cell 
lineage markers, the t-SNE plot was separated into 3 broad groups: T cells (expressing 
CD3e, CD4, or CD8a), B cells (expressing B220), and myeloid/NK cells (expressing 
CD335, F4/80, CD11b, CD11c, Ly6C, or Ly6G) (Figure 1B). Correlation analysis 
showed a positive correlation between age and the percentage of T cells (ρ = 0.8952, 
P
ρ
 < 0.0001) and B cells (ρ = 0.8216, P
ρ
 < 0.0001) in the adult mouse prostate (Figures 
1C and 1D). The increase in T and B lymphocytes with age was accompanied by a 
respective negative correlation between age and the percentage of myeloid/NK cells (ρ 
= -0.9197, P
ρ
 < 0.0001) in the adult mouse prostate (Figure 1E). These trends are 
consistent with the age-related increase in T and B lymphocytes and decrease in 
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myeloid and NK cells previously reported in 3- and 24-month-old mouse prostates by 
our group (Crowell et al., 2019).  
 
To provide more granularity to our analysis we performed unsupervised k-nearest 
neighbors clustering using the X-Shift algorithm to further subdivide the t-SNE plot into 
phenotypically-distinct immune cell clusters (Figure 2A and Figure S2B). The X-Shift 
algorithm was chosen because it optimizes the numbers of clusters to prevent over- and 
under-clustering (Samusik et al., 2016). The algorithm produced 29 immune cell 
clusters which were then subdivided by cell type. Expression of lineage markers was 
used to identify 24 of 29 immune cell clusters as T cells (CD3e+), B cells (B220+ and 
CD19+), NK cells (CD335+), and myeloid cells (any combination of F4/80+, CD11b+, 
CD11c+, or Ly6G+) (Figures 2A–2E). The 5 remaining clusters were classified as 
unknown due to expression of both T cell and myeloid cell markers (U1), lack of a 
strong signal for any lineage-specific markers (U2–U3, U5) or mild staining for every 
marker (U4) (Figure 2A).  
 
We noticed 6 immune cell clusters with positive staining for both Ly6C and CD19 (T1, 
T8, B1, NK1, M4, U2) (Figure 2A). Since CD19 is only expected on B cells, expression 
on other cell types was thought to be unlikely (Engel et al., 1995). We plotted Ly6C 
against CD19 and found interference between the channels. At high levels of Ly6C, 
there was overflow of signal into the CD19 channel, resulting in a linearly proportional 
increase in signal between the two channels (Figure S3A). Ly6C was conjugated to 
neodymium-150, and CD19 was conjugated to erbium-166. These two lanthanide 
isotopes differ by 16 Da, consistent with known effects of oxidation of neodymium-150 
by oxygen-16 as the sample is ionized to plasma in the mass cytometer (Figure S3B) 
(Leipold et al., 2015). We checked every other combination of the 19 markers used and 
found no other instances of signal spillover (Figure S3C). The effects of signal spillover 
from Ly6C into CD19 taken into account, high Ly6C expression may be causing T1, T8, 
NK1, M4, and U2 to appear as CD19+. However, expression of the B cell marker B220 
by B1 indicates that its CD19 signal is likely true (Coffman and Weissman, 1981). 
 
Age-related changes in the mouse prostate immune compartment arise early in 
adulthood 
 
Having used unsupervised clustering to subdivide immune cells in the mouse prostate 
into distinct subsets, we next looked at how these populations change throughout 
adulthood. Spearman correlation analysis was performed to determine whether each 
immune cell cluster was enriched (ρ > 0) or depleted (ρ < 0) with age. We found that 
19/29 immune cell clusters were significantly correlated with age (ρ ≠ 0, P
ρ
 < 0.05). 
Consistent with the overall increase in T and B lymphocytes in the mouse prostate with 
age, 8/10 T cell clusters and 2/2 B cell clusters were significantly enriched with age. 
Similarly, we found that 1/2 NK cell clusters and 5/10 myeloid cell clusters had a 
significant negative correlation with age (Figure 3A and Table S1). There was an 
extreme outlier in the abundance of cluster M2 by one of the 9-month-old mice. When 
the outlier was excluded, we found a significant negative correlation (P
ρ
 < 0.05) 
between M2 abundance in the prostate and age (Figure S4). 
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 Principal component analysis was performed to assess the progression of changes to 
the mouse prostate immune microenvironment. Prostates from 3- and 6-month-old mice 
clustered together as did those from 12- and 16-month-old mice, demonstrating the 
similarity in immune microenvironments of prostates in these age groups (Figure 3B). 
Prostates from 9-month-old mice clustered between the other ages, demonstrating an 
intermediate immune phenotype at this age. These results show that there is a shift in 
the inflammatory microenvironment of the mouse prostate occurring between 6 and 12 
months of age. 
 
To validate these changes to the immune microenvironment of the mouse prostate, we 
performed a second CyTOF immunophenotyping experiment with a panel of the same 
markers and mice 4-, 9-, and 15-months-old (each n = 3) (Table S2). The 24 known 
immune cell clusters from the discovery experiment were matched to immune cells from 
the validation experiment, and Spearman correlation analysis was performed (Figure S5 
and Table S3). Four of the 24 immune cell clusters (T1, T3, B1, and M10) were 
validated (same sign for ρ and P
ρ 
< 0.05 in both discovery and validation experiments) 
(Figure 3C). Fifteen of the 24 immune cell clusters had the same direction of correlation 
with age in both the discovery and validation experiments but failed to meet the barrier 
of statistical significance in both experiments. The majority of these were significant in 
the discovery but not the validation experiments, likely due to the low statistical power of 
n = 3 in the validation. Overall, there was a statistically significant correlation between 
the sign of ρ for immune cell clusters in each experiment (p < 0.01, Fisher’s exact test), 
supporting the reproducibility of our CyTOF immunophenotyping (Figure 3C). 
 
Because CyTOF is not a widely available technique, we sought to provide a more 
accessible way to study these age-related immune microenvironment changes in the 
mouse prostate. Guided by the phenotypes of the validated immune cell clusters, a 
simpler gating scheme was constructed which can identify the 4 validated clusters (T1, 
T3, B1, and M10) and 5 additional clusters that were significant in the discovery 
experiment (T2, T7, T10, B2, and M9) using a reduced number of markers (Table 2 and 
Figure 4A). The reduced panel has fewer markers to be used with more widely 
accessible 12-color flow cytometry (De Rosa et al., 2003). Importantly, manual gating to 
reidentify these immune cell clusters in the discovery experiment produced populations 
with significant correlations with age (P
ρ 
< 0.0001) that are consistent with correlations 
found using X-Shift clustering (Figures 4B–4D). 
 
Mouse prostate and bladder share features of inflammaging 
 
We performed CyTOF on bladders and kidneys from 3- and 16-month-old mice (each n 
= 4) to compare aging of the prostate to other urogenital tissues with age-related cancer 
risk (Shariat et al., 2010; Vogelzang and Stadler, 1998). Immune cells from these 
tissues were included for X-Shift clustering so that we could examine age-related 
changes to the same 29 immune cell clusters as the prostate (Table S1). In the mouse 
bladder, we identified significant correlations between age and 17/29 immune cell 
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clusters (ρ ≠ 0, P
ρ
 < 0.05) (Figure S6A). The immune profiles of the 3- and 16-month-old 
mouse kidneys were similar, with only 5/29 immune cell clusters significantly correlated 
with age (Figure S6B). Principal component analysis was performed on the 3- and 16-
month old samples from the prostate, bladder, and kidney to assess the similarities in 
how different urogenital tissues age (Figure 5A). Three-month-old bladder and prostate 
clustered together as did 16-month-old bladder and prostate, suggesting these tissues 
are similar in how their immune microenvironments change with age. Both ages of 
kidney clustered together near the 16-month-old bladder, suggesting that the kidney 
immune microenvironment did not change with age and was most similar to the 16-
month-old bladder. 
 
To better understand these relationships, we compared the correlation coefficients (ρ) 
for each immune cell cluster, irrespective of p-value, in the prostate, bladder, and kidney 
(Figure 5B). Thirteen of 29 clusters were correlated with age in the same direction in all 
three tissues (all ρ > 0 or ρ > 0) (T1-T4, T9, B1-B2, NK1, M6, M8-M10, and U5). Among 
the other immune cell clusters, prostate and bladder shared more similarities to each 
other than to kidney (Figure 5B–5E and Figure S6C). These results demonstrate that 
the immune compartments of mouse urogenital tissues age differently and that the 
aging prostate more closely resembles the aging bladder than the kidney. 
 
DISCUSSION 
 
Inflammation in the prostate and aging are both associated with an increased risk for 
developing prostate cancer (Gurel et al., 2014; Sfanos and De Marzo, 2012). Our group 
and others have previously reported that the mouse prostate experiences an increase in 
immune cells as it ages, however the dynamics of how these changes occur were 
unclear (Bianchi-Frias et al., 2010; Crowell et al., 2019). In this study, we characterized 
how the inflammatory microenvironment of the adult mouse prostate changes during 
aging using highly-multiplexed single-cell mass cytometry. This dataset presents the 
most comprehensive profiling of the aging adult mouse prostate immune profile to date. 
 
By 3 months of age, male mice are sexually mature and the prostate has completed 
development (Marker et al., 2003). At this age, myeloid cells make up the majority of 
immune cells in the mouse prostate (Figure 1E). As mice age, the immune compartment 
of the mouse prostate undergoes an expansion of T and B lymphocytes resulting in a 
profound shift in the tissue’s immunological milieu (Figures 1C and 1D). Importantly, this 
age-related expansion of lymphocytes in the prostate happens in contrast to the age-
related myeloid bias of hematopoiesis (Mann et al., 2018). As mice age, different 
processes including bone marrow stem cell niche remodeling, inflammatory cytokines, 
and telomere dysfunction skew hematopoiesis towards myeloid lineages (Ergen et al., 
2012; Ho et al., 2019; Ju et al., 2007). Aging is also associated with involution of the 
thymus, resulting in reduced production of naïve T cells (Palmer, 2013). Additionally, B 
cell development is impaired in aged mouse bone marrow (Zharhary, 1988). These 
many processes converge to reduce lymphocyte output and increase myeloid 
differentiation. The contrasting lymphocyte expansion in the mouse prostate suggests 
that the prostate contains a somewhat unique aging immune microenvironment. 
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 We used 19 surface markers to identify 29 phenotypically-distinct clusters of immune 
cells in the mouse prostate (Figure 2). We then tracked how the abundance of each 
immune cell cluster changes during adult mouse aging by comparing tissue aged 3-, 6-, 
9-, 12-, and 16-months. We found that there is a progressive change in the immune 
microenvironment of the mouse prostate taking place between 6 and 12 months of age 
(Figures 3A and 3B). A separate validation experiment demonstrated that the majority of 
age-related changes to specific immune cell clusters were reproducible (Figure 3C). 
Future studies will be necessary to determine the mechanisms promoting an altered 
prostate immune compartment between 6 and 12 months of age. 
 
Our findings reveal that aging of the mouse prostate immune compartment is complex. 
In the aging mouse prostate, the proportion of total T and B cells increases as the 
proportion of total NK and myeloid cells decreases (Figures 1C–1E). Analyzing these 
changes at the more granular level of immune cell cluster shows greater complexity in 
these changes to the immune microenvironment. While all B cell clusters were enriched 
with age, we identified T cell clusters which did not change or were reduced in 
abundance with age. Similarly, while the majority of NK and myeloid cell clusters 
decreased with age, we found NK and myeloid cell clusters which did not significantly 
change in proportion with age (Figure 3A). These findings clarify that a subset of 
immune cells clusters accounts for the overall increase in T and B lymphocytes and 
decrease in NK and myeloid cells with age.  
 
Though we used highly-multiplexed CyTOF to study changes to the prostate immune 
microenvironment, we sought to devise a simplified panel that could be accessible with 
more widely available technologies. We took the most reproducible immune cell cluster 
changes and designed a panel of 11 markers which can reidentify the same immune 
cell clusters that are significantly correlated with age (Table 2 and Figure 4). This 
reduced panel could be used to study changes to the mouse prostate immune 
microenvironment using more accessible 12-color flow cytometry (De Rosa et al., 
2003).  
 
Finally, we used CyTOF to survey the immune microenvironment of the aging mouse 
bladder and kidney to determine how the aging phenotype of the prostate compares to 
other urogenital tissues. Between the bladder and kidney, we found that the aging 
prostate’s immune compartment is more similar to the bladder (Figure 5 and Figure S6). 
The proximity of the prostate and bladder may explain their similar aging immune 
profiles. Both tissues are derived from the urogenital sinus, whereas the kidney 
develops from the ureteric bud and metanephric mesenchyme (McMahon, 2016; Staack 
et al., 2003). The similarity in immune compartment aging between mouse prostate and 
bladder may also be reflective of their shared developmental origin. Understanding what 
drives similar age-related changes to the immune compartment in prostate and bladder 
nay reveal common approaches to prevent inflammaging and reduce age-related 
disease risk. 
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LIMITATIONS OF THE STUDY 
 
In this study, we evaluated immune cells in the aging mouse prostate using mass 
cytometry to take advantage of its high-throughput single-cell data. This approach 
requires dissociation of the tissue to a single-cell suspension using mechanical and 
enzymatic means. As a result, we were only able to profile immune cells that could 
survive the dissociation protocol. Between different organs and ages, we assume that 
specific immune cell types are equally likely to survive the dissociation protocol, 
allowing for relative comparisons to still be made. Other approaches that preserve 
tissue architecture, like immunohistochemistry (IHC), immunofluorescence (IF), and 
imaging mass cytometry (IMC), may be necessary to detect cell types that may not 
survive long enough for CyTOF detection. 
 
For both weight and % CD45+ immune cells, there were time points whose mean values 
were greater than those at 3-months-old yet were not statistically significant (Figures 
S1A and S1B). The relatively low statistical power of Dunn’s test may be responsible for 
some intermediate ages not reaching the threshold of significance (Kromrey and La 
Rocca, 1995). Additional replicates would be useful in increasing the statistical power 
and determining whether these changes happen even earlier in adulthood than 12 
months of age. 
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FIGURE LEGENDS 
 
Figure 1. CyTOF immunophenotyping of the mouse prostate. 
 
(A) Workflow for prostate immunophenotyping using CyTOF. Mouse prostates of 
different ages were isolated, dissociated to single cells, and stained with a panel of 
heavy metal-tagged antibodies before data acquisition via mass cytometry. Bivariate 
plots show gating for single, live CD45+ immune cells before analysis using clustering 
algorithms (t-SNE and X-Shift). Percentages represent the fraction of events that are 
within the gate in each bivariate plot. 191Ir/193Ir labels DNA of all cells. 103Rh labels DNA 
of dead cells. This flowchart was adapted from a previous publication from our group 
(Crowell et al., 2019). 
 
(B) t-SNE plot generated from the immune cells from mouse prostate, bladder, and 
kidney. Left: Heat maps showing expression of selected lineage markers by immune 
cells clustered using t-SNE. Right: t-SNE plot separated into 3 broad groups of immune 
cells (T cells, B cells, and myeloid/NK cells). 
 
(C–E) Quantification of changes to the mouse prostate immune cell composition during 
adult aging for CD3+ T cells (C), B220+ B cells (D), and myeloid/NK cells (E). Spearman 
correlation coefficient (ρ) and associated p-value (P
ρ
) represent the correlation between 
% immune cell type and age. Data represents mean ± SD of 4 biological replicates at 
each age. Kruskal-Wallis, p < 0.01 (T cells, B cells, and Myeloid/NK cells). Dunn’s 
multiple comparisons test against 3-months-old, *p < 0.05, **p < 0.01.  
 
See also Figures S1 and S2. 
 
Figure 2. Unsupervised clustering of immune cells produces 29 phenotypically 
distinct clusters. 
 
(A) Heat map showing the phenotypes of the 29 immune cell clusters generated using 
X-shift clustering on immune cells detected from aging mouse prostates, bladders, and 
kidneys using CyTOF. Clusters were separated into T cells (CD3, CD4, CD8), B cells 
(B220, CD19), NK cells (CD335), myeloid cells (F4/80, CD11b, CD11c, and Ly6G) and 
unknown by expression of immune lineage markers. Shading represents mean marker 
expression transformed by arsinh(x). 
 
(B–E) Immune cell cluster expression of lineage markers for T cells (CD3) (B), B cells 
(B220) (C), NK cells (CD335) (D), and myeloid cells (CD11b and CD11c) (E). Data 
represents mean marker expression in each cluster transformed by arsinh(x) ± SD 
between clusters of the same broad immune cell type. Kruskal-Wallis, p < 0.001 (CD3), 
p < 0.05 (B220), p = 0.106 (CD335). Two-way ANOVA, p < 0.0001 (myeloid markers).  
 
See also Figures S2–S4. 
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Figure 3. The adult mouse prostate immune microenvironment changes 
progressively with age. 
 
(A) Heat map showing changes to immune cell cluster abundance in the aging adult 
mouse prostate, correlation with age (ρ), and associated p-value (P
ρ
). Shading indicates 
abundance represented as a row z-score except where Spearman correlation (ρ) is 
indicated. Data represents 4 biological replicates at each age. *p < 0.05, **p < 0.01., 
***p < 0.001, ****p < 0.0001. n.s., not significant, p ≥ 0.05. 
 
(B) Principal component analysis (PCA) was performed on immune cell cluster 
frequencies for mouse prostates at different ages. Ellipses represent 95% confidence 
intervals for 4 biological replicates at each age. PC, principal component. 
 
(C) Twenty-four clusters of known cell type were identified in a separate validation 
experiment with prostates from mice 4-, 9-, and 15-months-old (each n = 3), and 
correlation with age (ρ) and associated p-value (P
ρ
) were calculated. Left: Dot plot 
compares correlation coefficients for each immune cell cluster in the initial (discovery) 
and validation experiments. Coloring of points represents significance (P
ρ
). Right: 
Contingency table comparing the direction of correlation with age (ρ > 0 or ρ < 0) for 
identified immune cell clusters between the discovery and validation experiments. M3 
was not counted because ρ = 0 in the discovery experiment. Fisher’s exact test was 
performed to evaluate the distribution of clusters in the four quadrants of the graph. 
 
See also Figure S5 and Tables S1–S3. 
 
Figure 4. Simplified gating scheme to identify immune cell clusters that change in 
abundance with age in the mouse prostate. 
 
(A) Bivariate plots showing a simplified 11 marker panel (CD45, CD3e, CD4, CD8a, 
CD19, B220, F4/80, CD11b, CD11c, Ly6C and PD-1) used to identify 4 validated 
immune cell clusters (T1, T3, B1, and M10) and 5 others (T2, T7, T10, B2, and M9). 
 
(B–D) Quantification of immune cell subset abundance by proportion of total CD45+ 
cells in the mouse prostate identified using the simplified 11 marker panel separated 
into T cells (B), B cells (C), and myeloid cells (D). Data represents mean ± SD of 4 
biological replicates at each age. MΦ, macrophage. Spearman correlation coefficient (ρ) 
and associated p-value (P
ρ
) represent the correlation with age. Kruskal-Wallis, p < 0.05 
(T3, T10, B1, B2, M9), p < 0.01 (T1, T2, T7, M10). Dunn’s multiple comparisons test 
against 3-months-old, *p < 0.05, **p < 0.01, ***p < 0.001.  
 
Figure 5. Comparison of age-related changes to the immune microenvironment of 
the mouse bladder, kidneys, and prostate. 
 
(A) Principal component analysis (PCA) was performed on immune cell cluster 
frequencies for mouse prostates, bladders, and kidneys at 3- and 16-months-old. 
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Ellipses represent 95% confidence intervals for 4 biological replicates at each age and 
tissue. PC, principal component. 
 
(B) Heat map showing correlations with age (ρ) for immune cells clusters from mouse 
prostate, bladder, and kidneys irrespective of p-value. Shading represents Spearman 
correlation (ρ). 
 
(C–E) Quantification of immune cell cluster abundance at 3 and 16 months of age in 
mouse prostate, bladder, and kidney separated into T cells (C), B cells (D), and myeloid 
cells (E). Mann Whitney U test between 3- and 16-months-old, *p < 0.05. Data 
represents mean ± SD of 4 biological replicates at each age and tissue. 
 
See also Figure S6 and Table S1.  
 
EXCEL TABLE TITLES 
 
Table S1. Abundance of X-Shift-generated immune cell clusters in the aging 
mouse prostate, bladder, and kidney from the discovery experiment. Related to 
Figures 3 and 5. 
 
Table S3. Abundance of phenotypically matched immune cell clusters in the 
aging mouse prostate from the validation experiment. Related to Figure 3. 
.CC-BY-NC-ND 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted June 20, 2020. . https://doi.org/10.1101/2020.06.18.160556doi: bioRxiv preprint 
TABLES 
 
Table 1. CyTOF immunophenotyping antibody panel for discovery experiment. 
 
Label Target Clone Conjugation Source 
89Y CD45 30-F11 Pre-conjugated Fluidigm 
139La CD27 LG.3A10 Maxpar kit BioLegend 
141Pr Ly6G 1A8 Pre-conjugated Fluidigm 
146Nd F4/80 BM8 Pre-conjugated Fluidigm 
147Sm CD80 (B7-1) 16-10A1 Maxpar kit BioLegend 
148Nd CD11b M1/70 Pre-conjugated Fluidigm 
150Nd Ly6C HK1.4 Pre-conjugated Fluidigm 
152Sm CD3e 145-2C11 Pre-conjugated Fluidigm 
153Eu CD274 (PD-L1) 10F.9G2 Pre-conjugated Fluidigm 
154Sm CD152 (CTLA-4) UC10-4B9 Pre-conjugated Fluidigm 
155Gd CD25 3C7 Maxpar kit BioLegend 
156Gd CD4 RM4-5 Maxpar kit BioLegend 
159Tb CD279 (PD-1) 29F.1A12 Maxpar kit BioLegend 
166Er CD19 6D5 Pre-conjugated Fluidigm 
167Er CD335 (NKp46) 29A1.4 Pre-conjugated Fluidigm 
168Er CD8a 53-6.7 Pre-conjugated Fluidigm 
172Yb CD86 (B7-2) GL1 Pre-conjugated Fluidigm 
176Yb CD45R (B220) RA3-6B2 Pre-conjugated Fluidigm 
209Bi CD11c N418 Pre-conjugated Fluidigm 
 
Table 2. Simplified panel for identifying immune cells in the mouse prostate that 
change with age. 
 
Marker 
CD45 
CD3e 
CD4 
CD8a 
F4/80 
CD11b 
CD11c 
B220 
CD19 
Ly6C 
PD-1 
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